TFAM is a novel mediator of immunogenic cancer cell death

@article{Yang2018TFAMIA,
  title={TFAM is a novel mediator of immunogenic cancer cell death},
  author={Minghua Yang and Changfeng Li and Shan Zhu and Lizhi Cao and Guido Kroemer and Herbert J. Zeh and Daolin Tang and Rui Kang},
  journal={Oncoimmunology},
  year={2018},
  volume={7}
}
Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. [] Key Result The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner.
The molecular machinery of regulated cell death
TLDR
The in-depth comprehension of each of these lethal subroutines and their intercellular consequences may uncover novel therapeutic targets for the avoidance of pathogenic cell loss.
Cell death in pancreatic cancer: from pathogenesis to therapy
TLDR
The complex role of regulated cell death (RCD) in pancreatic tumorigenesis and treatment is described and how RCD is reshaped in tumours at both molecular and metabolic levels is discussed to highlight the challenges and opportunities in this field.
Anticancer effects of anti-CD47 immunotherapy in vivo
TLDR
Monotherapy by CD47 blockade led to a reduction in tumor growth and an increase in overall survival and was at least as efficient as chemotherapy and that could be favorably combined with the anthracycline mitoxantrone in the context of carcinogen-induced orthotopic breast cancers.
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
TLDR
CDK1/2/5 inhibition by dinaciclib provides a novel strategy to overcome IFNG-triggered acquired resistance in pancreatic tumour immunity.
AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance.
TLDR
It is indicated that activating the AHR signaling pathway reshaped the metabolism in MDS/AML cells, thus contributing to the resistance to cytarabine.
Deubiquitinating Enzyme-Mediated Signaling Networks in Cancer Stem Cells
TLDR
The role of DUBs in regulating several signaling network in cancer stem cells is summarized and the disassembly of ubiquitin chains from specific substrates by deubiquitinating enzymes (DUBs) is crucial.
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment
Cancer treatment has rapidly entered the age of immunotherapy, and it is becoming clear that the effective therapy of established tumors necessitates rational multi-combination immunotherapy
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
TLDR
It is suggested that RIP3 and MLKL can contribute to ICD signaling and tumor immunogenicity.
Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy
TLDR
It is demonstrated that HMGB1 (high mobility group box 1), normally a nuclear protein, is a crucial regulator of TNFSF10/TRAIL (tumor necrosis factor [ligand] superfamily, member 10)-induced cancer cell death, and PARP1 acts as a prominent upstream regulator ofHMGB1-mediated autophagy and maintains a homeostatic balance between apoptosis and autophileagy.
Immunogenic cell death in cancer therapy.
TLDR
It is postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies and its subversion by pathogens.
Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia
TLDR
The findings indicate that the autophagy inhibitor spautin-1 enhances IM-induced apoptosis by inactivating PI3K/AKT and activating downstream GSK3β, leading to downregulation of Mcl-1 and Bcl-2, which represents a promising approach to improve the efficacy of IM in the treatment of patients with CML.
Immunogenic death of colon cancer cells treated with oxaliplatin
TLDR
OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients, and both oxaliplatin and cisplatin were equally efficient in triggering HMGB1 release.
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
TLDR
A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
TLDR
It is demonstrated that autophagy, which is often disabled in cancer, is dispensable for chemotherapy-induced cell death but required for its immunogenicity, and increased extracellular ATP concentrations improve the efficacy of antineoplastic chemotherapies when Autophagy is disabled.
Calreticulin exposure dictates the immunogenicity of cancer cell death
TLDR
It is shown that anthracyclin-induced CRT translocation induces the rapid, preapoptotic translocation of calreticulin (CRT) to the cell surface and is identified as a key feature determining anticancer immune responses.
Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
TLDR
The aurora kinase inhibitor CCT137690 is identified as an agent that induces necrosis-like death in PDAC cells, via RIPK1, RIPK3, and MLKL, and expression of AURKA and GSK3β associate with patient survival times and might be targeted for treatment of pancreatic cancer.
...
...